Overview and History of NOLVAMED 20 (Tamoxifen citrate)
NOLVAMED 20 (Tamoxifen citrate) belongs to a class of drugs known as selective Estrogen receptor modulators (called SERMs for short). Selective Estrogen receptor modulators belong to an even broader category of drugs known as anti-estrogens. The other subcategory of drug under the anti-estrogens category is known as aromatase inhibitors (AIs), such as AROMAMED 25 (Exemestane) and ARIMIMED 1 (Anastrozole).
AIs and SERMs make up anti-estrogens, also known as Estrogen antagonists or Estrogen blockers. Aromatase inhibitors are very different from SERMs in their action and how they deal with the issues of Estrogen control. There is a misconception among the anabolic steroid using community that SERMs, such as NOLVAMED 20 (Tamoxifen citrate) and CLOMIMED 50 (Clomiphene citrate), serve to lower estrogen levels. That is not true. SERMs serve to block the action of Estrogen at the receptor sites in breast tissue by occupying the receptor sites in place of Estrogen so that Estrogen itself cannot exert its effects there through receptor site binding. On the contrary, SERMs will also act as Estrogens at receptor sites at other cells in other areas of the body (for example the liver, like NOLVAMED 20 (Tamoxifen citrate). SERMs do not lower circulating levels of Estrogen in blood plasma. Aromatase inhibitors do this by eliminating the production of Estrogen through binding to and disabling the aromatase enzyme, which is the enzyme responsible for the conversion (or aromatization) of androgens into Estrogen.
NOLVAMED 20 (Tamoxifen citrate) is specifically a non-steroidal SERM which is part of the triphenylethylene family of compounds that exhibits both Estrogen agonist and Estrogen antagonistic effects on the body. Although NOLVAMED 20 (Tamoxifen citrate) might block the effect of Estrogen at the cellular level in certain tissues, it can enhance Estrogenic effects in other areas of the body. These effects can be both: positive and negative. NOLVAMED 20 (Tamoxifen citrate) exhibits Estrogenic effects in the liver, which is a positive effect, as it results in a positive change in cholesterol profiles. The area of concern during the usage of NOLVAMED 20 (Tamoxifen citrate) is breast tissue, where the drug acts as a very strong anti-Estrogen. This is where it is utilized in the medical field, as a first-line treatment in Estrogen-responsive female breast cancer patients. NOLVAMED 20 (Tamoxifen citrate) is even utilized in females that do not possess breast cancer but are known as being in a high-risk category (due to hereditary genetics or otherwise) as a preventative measure.
NOLVAMED 20 (Tamoxifen citrate) possesses other attractive effects, such as its ability to increase circulating levels of endogenous gonadotropins Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH), and through this, increasing the endogenous production of Testosterone. This is a great example of the mixed Estrogen antagonistic and agonistic properties of NOLVAMED 20 (Tamoxifen citrate), where it works to block the ability for Estrogen to bind to receptors at the hypothalamus. Such actions result in the manipulation of the negative feedback loop of the HPTA (Hypothalamic Pituitary Testicular Axis), and in the increased output of gonadotropins (the hormones that signal the testes to begin or increase the output of Testosterone production). Because of this reason NOLVAMED 20 (Tamoxifen citrate) is considered an essential component of a PCT (Post Cycle Therapy) cycle to restore the function of endogenous Testosterone production.
Tamoxifen citrate was developed by ICI in 1962 and shortly afterward was released onto the prescription drug market in the United States. The very first application of this compound in medicine was the treatment of female infertility. Later, after various clinical testing, NOLVAMED 20 (Tamoxifen citrate) was found to be highly effective in the treatment of breast cancer patients. Tamoxifen citrate has spread internationally. Thousands of different brands and generics of it have been created.
Chemical Characteristics of NOLVAMED 20 (Tamoxifen citrate)
NOLVAMED 20 (Tamoxifen citrate) is a non-steroidal selective Estrogen receptor modulator (SERM) that possesses both mixed agonistic and antagonistic properties concerning Estrogen in different areas of the body. NOLVAMED 20 (Tamoxifen citrate) is part of the family of compounds known as triphenylethylene compounds. CLOMIMED 50 (Clomiphene citrate) is also a member of this family and a very closely related compound to NOLVAMED 20 (Tamoxifen citrate).
Properties of NOLVAMED 20 (Tamoxifen citrate)
Being a SERM, NOLVAMED 20 (Tamoxifen citrate) does not reduce circulating Estrogen levels in the body but instead serves to occupy the receptor sites in breast tissue so that Estrogen itself cannot bind to these receptors due to NOLVAMED 20 (Tamoxifen citrate) stronger binding strength to it. NOLVAMED 20 (Tamoxifen citrate) acts as a ‘fake’ Estrogen that acts as a placeholder at the receptor sites in breast tissue. As a result, Estrogen cannot activate gene transcription in the cells there to formulate gynecomastia, and any existing Estrogen that has already bound to receptor sites will essentially be ‘forced’ out of the receptor sites by NOLVAMED 20 (Tamoxifen citrate) which then occupies the receptor site instead. This quality is perfect for anabolic steroid users that wish to eliminate and reverse formulating gynecomastia in its early stages, as well as for those users which are very sensitive to the gynecomastia side effect of rising Estrogen levels that might wish to use NOLVAMED 20 (Tamoxifen citrate) as a preventative measure. This is the primary function of NOLVAMED 20 (Tamoxifen citrate) and is the main desired effect that anabolic steroid using bodybuilders and athletes utilize it for.
NOLVAMED 20 (Tamoxifen citrate) will not serve to block or reduce any other Estrogenic side effects, as it serves only to block Estrogenic activity at the breast tissue area (when major Estrogenic side effects are concerned). The same like any other SERMs, NOLVAMED 20 (Tamoxifen citrate) does not serve to reduce bloating, water retention, rising blood pressure (as a result of water retention), or acne formation – these are all side effects resultant from increasing blood plasma Estrogen levels.
NOLVAMED 20 (Tamoxifen citrate) Side Effects
NOLVAMED 20 (Tamoxifen citrate) is a compound that is tolerated quite well by the majority of users. Like with any other compound, there are some potential side effects to be aware of. Because of the difference in androgen and Estrogen receptor proliferation among cells in the male and female bodies, NOLVAMED 20 (Tamoxifen citrate) can generate quite different effects depending on the gender of the user. This is the reason why there are many negative experiences with NOLVAMED 20 (Tamoxifen citrate) side effects among female users. Anyway, this is a different story in comparison to its use among bodybuilders and athletes using NOLVAMED 20 (Tamoxifen citrate) as an ancillary compound surrounding their anabolic steroid use.
The official prescription documentation for NOLVAMED 20 (Tamoxifen citrate) side effects when it is used as a female breast cancer treatment drug includes hot flashes, vaginal itching, upset stomach, headaches, dizziness, bone and joint pains, and edema. Less common side effects may include cholesterol changes, altered white blood cell count, altered platelet count, skin rashes, endometrial changes, deep vein thrombosis, and pulmonary embolism. The mentioned NOLVAMED 20 (Tamoxifen citrate) side effects are practically a non-concern for male users, as the overwhelming majority of said side effects are reportedly seldom experienced among men users.
Dosages and Administration of NOLVAMED 20 (Tamoxifen citrate)
In the medical field, NOLVAMED 20 (Tamoxifen citrate) is used as a medication in the treatment of 6 different types of female breast cancer. The prescription dosing and administration of NOLVAMED 20 (Tamoxifen citrate) in these cases call for 10 – 20mg taken twice per day, in the morning and evening respectively.
Within the bodybuilding and performance enhancement world, NOLVAMED 20 (Tamoxifen citrate) is primarily used as an ancillary aid to combating, reducing, and/or preventing the development of Gynecomastia. This usually happens when a particularly moderate or aromatizable anabolic steroid is utilized in a cycle. Dosing of NOLVAMED 20 (Tamoxifen citrate) in this case is approximately 10 – 30mg per day. The common dosing tends to be 20mg per day of NOLVAMED 20 (Tamoxifen citrate). That must be noted, that higher dosages of NOLVAMED 20 (Tamoxifen citrate), greater than 20 – 40mg per day, does not produce any greater or faster effect on reducing or preventing gynecomastia.
The other purpose for NOLVAMED 20 (Tamoxifen citrate) use among bodybuilders and athletes is its ability to stimulate and increase the male production of endogenous Testosterone, as many studies have shown. It does so by acting on the pituitary and hypothalamus gland in the brain and signaling an increase in production of FSH (Follicle Stimulating Hormone) and LH (Luteinizing Hormone), which then signals the testes to produce Testosterone. NOLVAMED 20 (Tamoxifen citrate) is usually administered during PCT, which is immediately after the anabolic steroid cycle is complete and all anabolic steroids are clear from the individual’s system. The dosage is 20 – 40mg per day, the cycle length of approximately 4 – 6 weeks. Studies have shown that venturing higher than 20 – 40mg per day does not generate any significantly greater amount of Testosterone production.
NOLVAMED 20 (Tamoxifen citrate) is usually included with the administration of at least one or two other Testosterone stimulating compounds during PCT (such as an aromatase inhibitor, usually AROMAMED 25 (Exemestane), and/or HCG) to enhance its effects on promoting proper HPTA function following the conclusion of a cycle. The utilization of NOLVAMED 20 (Tamoxifen citrate) during a cycle will not counter-act the Testosterone suppression of anabolic steroid use and will not keep endogenous Testosterone production going amidst the use of suppressive compounds. It is therefore not recommended to do that, as it would be useless. NOLVAMED 20 (Tamoxifen citrate) possesses an extremely long half-life for an oral compound, approximately 5 – 7 days. Some studies even demonstrated a longer half-life of 14 days. Because of this, there is no requirement to split dosages throughout the day. It is safe to consume NOLVAMED 20 (Tamoxifen citrate) together with food or on an empty stomach.
Chemical info / Information
Tamoxifen Citrate (AKA Nolvadex)
Chemical Name: (Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
Molecular Weight: 371.515 g/mol or 563.638 g/mol (citrate salt)
Original Manufacturer: ICI
Elimination half-life: 5 – 7 days (some reports as long as 14 days)
Detection Time: 2 months
Anabolic Rating: N/A
Androgenic Rating: N/A